ArticleInternational microbiology : the official journal of the Spanish Society for Microbiology2026
Engineered microorganisms for environmental release: current situation and future perspectives.
Article in International microbiology : the official journal of the Spanish Society for Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Environmental Release of Genetically Intervened Microorganisms: Towards a New Narrative.Microbial biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Engineered microorganisms for environmental release (EMERs) hold a considerable potential for bioremediation of sites polluted with urban and industrial emissions. The growing availability of EMERs with phenotypes that can help recovering polluted sites and degraded ecosystems could become a phenomenal tool to tackle some of the most pressing contamination problems at very different scales worldwide. Yet, while their delivery to diverse environmental targets could have an immense benefit, the regulatory roadmap for permitting release-in particular in the European Union-is controlled by strict policies which become actual deterrents for the development of the field. In this Perspective, we have mapped the current state of regulatory affairs and entertain ways of moving from the existing legislation on genetic engineering to an informed discussion about the future of this technology, highlighting several important aspects of the new generation of molecular tools for precision genetic engineering. Furthermore, we advocate advancing towards a fresh mindset in which EMERs are not perceived as artificial intrusions into the natural world, but as our main allies to combat much of the damage that we have inflicted to the planet.
Indexed as
Identifiers
42541690What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.